相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Turning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors
Anupa K. Patel et al.
CURRENT DIABETES REPORTS (2010)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
L. Zhang et al.
DIABETES OBESITY & METABOLISM (2010)
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
M. Obermeier et al.
DRUG METABOLISM AND DISPOSITION (2010)
Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study
Elizabeth K. Hussey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
Elizabeth K. Hussey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Glucose Control by the Kidney: An Emerging Target in Diabetes
Olivera Marsenic
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Emerging therapies for metabolic diseases-the focus is on diabetes and obesity
Thomas E. Hughes
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats
Yoshikazu Fujimori et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice
Kenji Katsuno et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Dapagliflozin: an emerging treatment option in type 2 diabetes
Mark Kipnes
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Recent and Emerging Anti-Diabetes Targets
Michael L. Mohler et al.
MEDICINAL RESEARCH REVIEWS (2009)
Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes
S. A. Jabbour et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
Yoshikazu Fujimori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Thiazolidinediones, insulin resistance and obesity: finding a balance
J. Wilding
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor γ agonist, on insulin resistance in Zucker fatty rat
H Minoura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats
K Ueta et al.
LIFE SCIENCES (2005)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Pyrazole-O-glucosides as novel Na+-glucose cotransporter (SGLT) inhibitors
K Ohsumi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Molecular analysis of the SGLT2 gene in patients with renal glucosuria
R Santer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Current therapies and emerging targets for the treatment of diabetes
AS Wagman et al.
CURRENT PHARMACEUTICAL DESIGN (2001)
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095
K Arakawa et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
分享论文
